Trial Outcomes & Findings for QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT) (NCT NCT05488470)

Last Updated: 2025-05-13

Results Overview

The QT intervals during antiarrhythmic loading will be compared for all patients with available LINQ ECG from the baseline anti arrhythmic loading hospitalization to analyze QT changes that may be caused due to antiarrhythmic drugs.

Recruitment status

COMPLETED

Target enrollment

22 participants

Primary outcome timeframe

Assessed in the 2-hr period after each of the first four doses, difference between the maximum and minimum QTc interval reported

Results posted on

2025-05-13

Participant Flow

Participant milestones

Participant milestones
Measure	All Subjects Anti-arrhythmic loading event
Overall Study STARTED	22
Overall Study COMPLETED	18
Overall Study NOT COMPLETED	4

Reasons for withdrawal

Reasons for withdrawal
Measure	All Subjects Anti-arrhythmic loading event
Overall Study Physician Decision	2
Overall Study Withdrawal by Subject	1
Overall Study Death	1

Baseline Characteristics

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Subjects With Completed Baseline Anti Arrhythmic Loading Hospitalization n=21 Participants Characteristics of Subjects with completed Baseline Anti Arrhythmic Loading Hospitalization
Age, Categorical <=18 years	0 Participants n=99 Participants
Age, Categorical Between 18 and 65 years	4 Participants n=99 Participants
Age, Categorical >=65 years	17 Participants n=99 Participants
Age, Continuous	71.5 years n=99 Participants
Sex: Female, Male Female	7 Participants n=99 Participants
Sex: Female, Male Male	14 Participants n=99 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=99 Participants
Race (NIH/OMB) Asian	0 Participants n=99 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=99 Participants
Race (NIH/OMB) Black or African American	0 Participants n=99 Participants
Race (NIH/OMB) White	20 Participants n=99 Participants
Race (NIH/OMB) More than one race	0 Participants n=99 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=99 Participants
Region of Enrollment United States	21 participants n=99 Participants
Medical History Transient Ischemic Attack	1 participants n=99 Participants
Medical History Thromboembolism	1 participants n=99 Participants
Medical History Stroke	2 participants n=99 Participants
Medical History Peripheral Artery Disease	2 participants n=99 Participants
Medical History Myocardial Infarction	4 participants n=99 Participants
Medical History Hypertension	20 participants n=99 Participants
Medical History Diabetes	7 participants n=99 Participants
Medical History Coronary Artery Disease	8 participants n=99 Participants
Medical History Congestive Heart Failure	7 participants n=99 Participants
Medical History Cancer	1 participants n=99 Participants
Medical History Aortic Plaque	1 participants n=99 Participants
Medical History Atrial Fibrillation	21 participants n=99 Participants
Medical History Atrial Flutter	5 participants n=99 Participants

PRIMARY outcome

Timeframe: Assessed in the 2-hr period after each of the first four doses, difference between the maximum and minimum QTc interval reported

Population: 8 patients (avg. age 68±6.5 years, 63% males) with available LINQ ECG data during the anti arrhythmic loading hospitalization.

Outcome measures

Outcome measures
Measure	QTc Interval Trends Observed During the Anti Arrhythmic Loading Hospitalization n=8 Participants The maximum QTc interval in the 2-hr period after each of the first four anti arrhythmic doses.
QT Intervals During Antiarrhythmic Loading Hospitalization	21.8 milliseconds Standard Deviation 9.4

Adverse Events

All Subjects

Serious events: 2 serious events

Other events: 0 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	All Subjects n=21 participants at risk All Subjects Enrolled
Renal and urinary disorders Hypokalemia	4.8% 1/21 • Number of events 1 • 90 days
Cardiac disorders Adverse Drug Reaction	4.8% 1/21 • Number of events 1 • 90 days

Other adverse events

Adverse event data not reported

Additional Information

Antony Chu, M.D., FACC, FAHA, FHRS, FACP, Director of Complex Ablation - Arrhythmia Services Section

Division of Cardiology at the Rhode Island and Miriam Hospital, Warren Alpert School of Medicine, Brown University

Phone: 401-444-8689

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place